Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $134.30 Consensus PT from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $134.30.

A number of research analysts recently weighed in on ORKA shares. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. HC Wainwright reiterated a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. BTIG Research reissued a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Barclays boosted their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, April 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $107.96 on Wednesday. The business has a 50-day moving average of $91.82 and a 200 day moving average of $65.23. Oruka Therapeutics has a 12 month low of $14.34 and a 12 month high of $115.51. The stock has a market capitalization of $7.15 billion, a price-to-earnings ratio of -53.18 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics will post -2.27 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the sale, the insider owned 32,718 shares in the company, valued at approximately $2,266,703.04. This trade represents a 19.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 83,116 shares of company stock valued at $6,636,533. 23.49% of the stock is currently owned by company insiders.

Institutional Trading of Oruka Therapeutics

Large investors have recently made changes to their positions in the company. Nykredit A S purchased a new position in Oruka Therapeutics in the second quarter worth approximately $29,000. Orion Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $91,000. Royal Bank of Canada increased its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $37,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $39,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.